Focus: Formosa Pharmaceuticals is a Taiwan-based public pharmaceutical company focused on nanoparticle technology and specialty therapeutics, with current portfolio strength in oncology and emerging neurology programs.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Formosa Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Formosa Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic/ANDA tubulin disruptor in post-exclusivity phase; anchors current revenue but faces commoditization pressure.
Help build intelligence for Formosa Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Formosa Pharma files European trial application for Kadcyla biosimilar TSY-110 - BioSpectrum Asia
Formosa Pharma files European trial application for Kadcyla biosimilar TSY-110 BioSpectrum Asia
Formosa Pharmaceuticals Files European CTA for TSY-110, Potential First Kadcyla Biosimilar in Regulated Markets - BioPharma APAC
Formosa Pharmaceuticals Files European CTA for TSY-110, Potential First Kadcyla Biosimilar in Regulated Markets BioPharma APAC
Formosa Pharma files European trial application for Kadcyla biosimilar TSY-110 - BioSpectrum Asia
Formosa Pharma files European trial application for Kadcyla biosimilar TSY-110 BioSpectrum Asia
Formosa Pharmaceuticals Files EU Application for Trastuzumab Emtansine Biosimilar TSY-110 - BioPharm International
Formosa Pharmaceuticals Files EU Application for Trastuzumab Emtansine Biosimilar TSY-110 BioPharm International
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers - PR Newswire
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers PR Newswire
Samil Pharmaceutical signs Vietnam licensing deal for postoperative eye drop - Korea Biomedical Review
Samil Pharmaceutical signs Vietnam licensing deal for postoperative eye drop Korea Biomedical Review
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub